Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
David Cella, Robert J. Motzer, Cristina Suárez, Steven I. Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel Wallace, Burçin Şimşek, Joshua Zhang, Cristina Ivanescu, Andrea B. Apolo, Toni K. Choueiri
Topics & Concepts
CabozantinibSunitinibNivolumabMedicineRenal cell carcinomaInternal medicineOpen labelOncologyUrologyRandomized controlled trialImmunotherapyCancerRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis